Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force by Chou, Roger et al.
Portland State University 
PDXScholar 
OHSU-PSU School of Public Health Faculty 
Publications and Presentations OHSU-PSU School of Public Health 
3-2020 
Screening for Hepatitis C Virus Infection in 
Adolescents and Adults: Updated Evidence Report 
and Systematic Review for the US Preventive 
Services Task Force 
Roger Chou 
Oregon Health & Science University 
Tracy Dana 
Oregon Health & Science University 
Rongwei Fu 
Oregon Health & Science University 
Bernadette Zahker 
Oregon Health & Science University 
Jesse Wagner 
Oregon Health & Science University 
See next page for additional authors 
Follow this and additional works at: https://pdxscholar.library.pdx.edu/sph_facpub 
 Part of the Infectious Disease Commons, and the Virus Diseases Commons 
Let us know how access to this document benefits you. 
Citation Details 
Chou, R., Dana, T., Fu, R., Zakher, B., Wagner, J., Ramirez, S., ... & Jou, J. H. (2020). Screening for hepatitis C 
virus infection in adolescents and adults: updated evidence report and systematic review for the US 
Preventive Services Task Force. Jama, 323(10), 976-991. 
This Article is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School of 
Public Health Faculty Publications and Presentations by an authorized administrator of PDXScholar. For more 
information, please contact pdxscholar@pdx.edu. 
Authors 
Roger Chou, Tracy Dana, Rongwei Fu, Bernadette Zahker, Jesse Wagner, Shaun Ramirez, Sara Grusing, and 
Janice H. Jou 
This article is available at PDXScholar: https://pdxscholar.library.pdx.edu/sph_facpub/347 
Screening for Hepatitis C Virus Infection in Adolescents and Adults
Updated Evidence Report and Systematic Review
for the US Preventive Services Task Force
Roger Chou, MD; Tracy Dana, MLS; Rongwei Fu, PhD; Bernadette Zakher, MBBS, MPH; Jesse Wagner, MA;
Shaun Ramirez, MPH; Sara Grusing, BA; Janice H. Jou, MD, MHS
IMPORTANCE A 2013 review for the US Preventive Services Task Force (USPSTF) of hepatitis C
virus (HCV) screening found interferon-based antiviral therapy associated with increased
likelihood of sustained virologic response (SVR) and an association between achieving an SVR
and improved clinical outcomes. New direct-acting antiviral (DAA) regimens are available.
OBJECTIVE To update the 2013 review on HCV screening to inform the USPSTF.
DATA SOURCES Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the
Cochrane Database of Systematic Reviews through February 2019, with surveillance through
September 2019.
STUDY SELECTION Randomized clinical trials (RCTs) and nonrandomized treatment studies of
HCV screening and DAA therapy; cohort studies on screening, antiviral therapy, and the
association between an SVR after antiviral therapy and clinical outcomes.
DATA EXTRACTION AND SYNTHESIS One investigator abstracted data; a second checked
accuracy. Two investigators independently rated study quality.
MAIN OUTCOMES AND MEASURES Mortality, morbidity, quality of life, screening and treatment
harms, and screening diagnostic yield.
RESULTS Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other
treatment studies, and 33 cohort studies, with a total of 179 230 participants, were included.
No study evaluated effects of HCV screening vs no screening. One new study since the 2013
review (n = 5917) found similar diagnostic yield of risk-based screening (sensitivity, 82%;
number needed to screen to identify 1 HCV case, 15) and birth cohort screening (sensitivity,
76%; number needed to screen, 29), assuming perfect implementation. Ten open-label
studies (n = 3292) reported small improvements in some quality-of-life and functional
outcomes (eg, less than 3 points on the 0 to 100 36-Item Short Form Health Survey physical
and mental component summary scales) after DAA treatment compared with before
treatment. Two cohort studies (n = 24 686) found inconsistent associations of antiviral
therapy vs no therapy with risk of hepatocellular carcinoma. Forty-nine treatment studies
(n = 10 181) found DAA regimens associated with pooled SVR rates greater than 95% across
genotypes, and low short-term rates of serious adverse events (1.9%) and withdrawal due to
adverse events (0.4%). An SVR after antiviral therapy was associated with decreased
adjusted risk of all-cause mortality (13 studies, n = 36 986; pooled hazard ratio [HR], 0.40
[95% CI, 0.28-0.56) and hepatocellular carcinoma (20 studies, n = 84 491; pooled HR, 0.29
[95% CI, 0.23 to 0.38]) vs no SVR.
CONCLUSIONS AND RELEVANCE Direct evidence on the effects of HCV screening on clinical
outcomes remains unavailable, but DAA regimens were associated with SVR rates greater
than 95% and few short-term harms relative to older antiviral therapies. An SVR after antiviral
therapy was associated with improved clinical outcomes compared with no SVR.
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I t has been estimated that from 2013 to 2016 approximately4.1 million people in the US were hepatitis C virus (HCV)antibody–positive, indicating past exposure, and that of
these, approximately 2.4 million had active infection.1 Persons
born between 1945 and 1965 were estimated to account for
approximately three-fourths of HCV infections. However, recent
increases in acute HCV incidence have mostly affected young per-
sons who inject drugs.2,3
In 2013, the US Preventive Services Task Force (USPSTF) rec-
ommended HCV screening for adults born between 1945 and 1965
(“birth cohort” screening) and those at high risk of infection (B
recommendation).4 The recommendation was based on the effec-
tiveness of then-current antiviral therapies with interferon. HCV
treatment has subsequently evolved to direct-acting antiviral (DAA)
regimens without interferon.
This evidence report was conducted to update the 2013 USP-
STF review on HCV screening in adults5,6 and a comparative effec-
tiveness review on antiviral treatments,7,8 to inform the USPSTF for
an updated recommendation statement. This report focused on cur-
rently recommended DAA regimens and was expanded to include
adolescents.
Methods
Scope of the Review
Detailed methods and evidence tables with additional study
details are available in the full evidence report at https://
www.uspreventiveservicestaskforce.org /Page/Document/
UpdateSummaryFinal/hepatitis-c-screening1. Figure 1 shows the
analytic framework and key questions (KQs) that guided the
review. KQs on prenatal HCV screening (KQ 1b) and interventions
to prevent vertical HCV transmission during labor and delivery
(KQ5) are addressed in the full report.
Data Sources and Searches
Ovid MEDLINE, the Cochrane Central Register of Controlled
Trials, and the Cochrane Database of Systematic Reviews were
searched from 2013 through February 2019 (eMethods 1 in the
Supplement). Searches were supplemented by reference list
review of relevant systematic reviews; studies from the prior
USPSTF review6,9 meeting inclusion criteria were carried forward.
Ongoing sur vei l lance was conduc ted to identif y major
studies published since February 2019 that may affect the
conclusions or understanding of the evidence and the related
USPSTF recommendation. The last surveillance was conducted
on September 20, 2019, and identified no studies affecting
review conclusions.
Study Selection
Two investigators independently reviewed titles, abstracts, and
full-text articles using predefined eligibility criteria. The popula-
tion for screening was asymptomatic adults and adolescents
without prior HCV infection. For treatment, to evaluate patients
more likely to be asymptomatic and identified by screening, inclu-
sion was restricted to studies in which 20% or less of patients had
cirrhosis at baseline (30% for cohort studies that controlled for
fibrosis stage). Randomized clinical trials (RCTs) of screening and
currently recommended DAA regimens vs placebo or an outdated
antiviral regimen10 were included. Because of few randomized
trials of DAA therapy vs placebo or an outdated antiviral regimen,
nonrandomized clinical research treatment studies of DAA
therapy (including those with a single group) and randomized
trials that compared different DAA regimens were also included.
The latter were classified as nonrandomized treatment studies
rather than randomized trials in this review because data from rel-
evant DAA regimens were analyzed separately (ie, the random-
ized comparison was not used). Cohort studies that controlled for
potential confounders were included for screening; for associa-
tions of antiviral therapy (including older regimens) with mortal-
ity, hepatocellular carcinoma, and cirrhosis; and for the associa-
tion between SVR after antiviral therapy and clinical outcomes.
Outcomes were mortality, morbidity (eg, cirrhosis, hepatic
decompensation, liver transplant, extrahepatic manifestations of
HCV infection), quality of life, HCV transmission, sustained viro-
logic response (SVR), harms, and screening yield (sensitivity and
number of new diagnoses per test performed). Studies that
focused on persons co-infected with HIV or hepatitis B virus,
patients receiving transplants, and persons with advanced kidney
disease were excluded.
Data Abstraction and Quality Rating
One investigator abstracted details about the study design,
patient population, setting, interventions, analysis, follow-
up, and results from each study. A second investigator reviewed
abstracted data for accuracy. Two independent investigators
assessed the quality of each study as good, fair, or poor using pre-
defined criteria developed by the USPSTF (eMethods 2 in the
Supplement).7 Discrepancies were resolved through a consensus
process. In accordance with the USPSTF Procedure Manual,7
studies rated poor quality because of critical methodological
limitations were excluded.
Data Synthesis
Random effects meta-analysis was performed to summarize the
proportion of patients experiencing SVR and adverse events using
a generalized linear mixed-effects model with a logit link. Analyses
were stratified according to DAA regimen. For SVR, separate
analyses were performed for each HCV genotype. A random-
effects (linear mixed-effects) meta-analysis was also performed on
adjusted hazard ratios (HRs) for SVR after antiviral therapy vs no
SVR and for clinical outcomes (mortality, liver-related mortality,
cirrhosis, and hepatocellular carcinoma). If necessary, the adjusted
HR for SVR vs no SVR was calculated from the adjusted HRs for
SVR and no SVR vs no treatment. Statistical heterogeneity was
assessed using the I2 statistic.11
Subgroup analyses were conducted on geographic setting
(US or Europe; multinational; other), fibrosis stage (cirrhosis
excluded or some patients [up to 20%] with cirrhosis), prior
treatment status (naive or experienced to interferon-based thera-
pies, boceprevir, or telaprevir), quality, and for cohort studies, full
adjustment for key confounding variables (age, sex, fibrosis stage,
and genotype). Stratified analyses were assessed for interactions
using a test for heterogeneity across subgroups. For the associa-
tion between DAA therapy and SVR rates, sensitivity analysis was
performed by excluding studies in which ribavirin or dasabuvir
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was not used as recommended. For the association between SVR
vs no SVR after antiviral therapy and clinical outcomes, sensitivity
analysis was performed by excluding cohort studies with poten-
tially overlapping populations to ensure that results were not sen-
sitive to double counting of patients. For analyses of harms, trials
of ribavirin-containing regimens were excluded except for
ombitasvir/paritaprevir/ritonavir/dasabuvir, which is recom-
mended for genotype 1b infection.
Meta-analyses were conducted using SAS version 9.4 (SAS In-
stitute Inc) and RevMan version 5.3.5 (Nordic Cochrane Centre), and
Figure 1. Analytic Framework: Screening for Hepatitis C Virus Infection in Adolescents and Adults
Key questions
a. Does screening for hepatitis C virus (HCV) infection in pregnant and nonpregnant adolescents and adults without known abnormal
liver enzyme levels reduce HCV-related mortality and morbidity or affect quality of life?
b. Does prenatal screening for HCV infection reduce risk of vertical transmission of HCV infection?d 
1
What are the harms of currently recommended antiviral treatments?8
What are the effects of interventions during labor and delivery or the perinatal period on risk of vertical transmission of HCV infection?d5
What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?6
What is the effectiveness of currently recommended antiviral treatments in achieving a sustained virologic response in patients
with HCV infection?
7
What is the association between experiencing sustained virologic response following antiviral treatment and reduction in risk
of HCV-related adverse health outcomes?
9
What is the effectiveness of different risk- or prevalence-based methods for screening for HCV infection on clinical outcomes?2
What is the yield (number of new diagnoses per tests performed) of 1-time vs repeat screening or alternative screening strategies
for HCV infection, and how does the screening yield vary in different risk groups?
3
What are the harms of screening for HCV infection (eg, anxiety and labeling)? 4
Asymptomatic pregnant
and nonpregnant
adolescents and adultsa
HCV+
HCV–
Screeningb
Staging
Antiviral treatment
Pregnancy
interventionsc
1, 2
3
7
9
5, 6
Harms of
interventions
8
Harms of
screening 
4
Mortality
Morbidity
Quality of life
Perinatal transmission
  of HCV
Health outcomesSVRStaged HCV
infection
Evidence reviews for the US Preventive Services Task Force (USPSTF)
use an analytic framework to visually display the key questions that the
review will address to allow the USPSTF to evaluate the effectiveness
and safety of a preventive service. The questions are depicted by linkages
that relate interventions and outcomes. A dashed line indicates a health
outcome that immediately follows an intermediate outcome. See USPSTF
Procedure Manual.7 HCV indicates hepatitis C virus; SVR, sustained
virologic response.
a Includes persons without abnormal laboratory values. Adolescents are defined
as those aged 12 to 17 years. Excludes persons living with HIV, transplant
recipients, and patients with renal failure.
b Defined as HCV antibody testing with confirmatory HCV RNA testing as
indicated.
c Includes interventions that may affect vertical transmission of HCV, such as
cesarean delivery, amniocentesis, fetal monitoring, management of ruptured
membranes, breastfeeding, and antiviral treatment.
d Addressed in the full evidence report.
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forest plots were created using Stata/SE version 14.0 (StataCorp).
All significance testing was 2-tailed; P < .05 was considered statis-
tically significant.
Results
Across all KQs addressed in this article, 8 (n = 3397) RCTs (in 6
publications),12-17 48 (n = 7132) nonrandomized treatment stud-
ies (in 45 publications),18-62 33 (n = 168 701) cohort studies,63-95
2 additional pooled analyses,96,97 and 1 retrospective study
(n = 5917)98 on the yield of alternative screening strategies in a
cohort of patients in a national survey were included (Figure 2).
Eighty-three studies12-62,64,66-74,77,79,81-83,85-92,95-98 were new for
this update, and 963,65,75,76,78,80,84,93,94 were carried forward
from the previous USPSTF review.
Benefits of Screening
Key Question 1a. Does screening for HCV infection in pregnant and
nonpregnant adolescents and adults without known abnormal liver
enzyme levels reduce HCV-related mortality and morbidity or affect
quality of life?
No study met inclusion criteria for this KQ.
Key Question 2. What is the effectiveness of different risk-
or prevalence-based methods for screening for HCV infection on
clinical outcomes?
No study met inclusion criteria for this KQ.
Key Question 3. What is the yield (number of new diagnoses
per tests performed) of 1-time vs repeat screening or alternative
screening strategies for HCV infection, and how does the screen-
ing yield vary in different risk groups?
A retrospective study (n = 5917) compared the yield of
risk-based HCV screening vs birth cohort screening in a cohort
of patients sampled from the National Health and Nutrition
Examination Survey.98 It found that applying risk-based
guidelines perfectly would screen 24.7% of the US general
population and identify 82% of HCV cases, with a number
needed to screen to identify 1 HCV case of 14.6. Applying the birth
cohort strategy would screen 45% of the general population and
identify 76% of cases, with a number needed to screen of 28.7.
No study evaluated the yield of 1-time vs repeat screening, the
yield of alternative screening strategies in different risk groups, or
the yield of currently recommended screening vs expanded
screening strategies.
Harms of Screening
Key Question 4. What are the harms of screening for HCV infec-
tion (eg, anxiety and labeling)?
No study compared harms of HCV screening vs no screening.
Poor-quality evidence from the prior USPSTF review suggested
potential negative psychological and social effects of screening
but was uncontrolled and did not meet inclusion criteria for this
update.
Benefits of Treatment
Key Question 6. What is the effectiveness of currently recom-
mended antiviral treatments in improving health outcomes in pa-
tients with HCV infection?
Adults
Quality of Life/Function | Ten open-label treatment studies
(n = 2404) reported quality-of-life and functional outcomes
before and after receipt of current DAA regimens (eTable 1 in the
Supplement). Seven studies were included in 2 pooled
analyses,95,96 and there were 3 additional studies (reported in 2
publications).12,99
At 12 weeks after treatment, 2 pooled analyses found
sofosbuvir/velpatasvir (4 trials) or sofosbuvir/ledispavir (3 trials)
associated with improvements in some measures of quality of
life or function compared with before treatment, though differ-
ences were small (eg, less than 3 points on the 36-Item Short
Form Health Survey physical and mental component summary
scales [range, 0-100 points] or 0.04 to 0.05 points on the
6-Dimensional Health State Form health utility scale), and not all
differences were statistically significant.95,96 Results were similar
in 2 studies of ombitasvir/paritaprevir/ritonavir/dasabuvir12 or
elbasvir/grazoprevir.99
Mortality | Thirty-one treatment studies (in 28 publications;
n = 3848) reported mortality at 12 to 36 weeks after completion of
DAA therapy but were not designed to assess this
outcome.14-19,24,25,27,28,30-32,36,37,39,41-44,46,48,49,51-55 Twenty-one
studies reported no deaths, and the remaining 10 studies reported
17 deaths (0.4% overall. Ten deaths occurred in 3 studies of per-
sons reporting recent injection drug use or use of opioid substitu-
tion therapy.31,32,55
Other Clinical Outcomes | Three cohort studies (n = 58 892) evalu-
ated other clinical outcomes (eTable 2 in the Supplement).67,68,83
Follow-up ranged from 1.1 to 7.4 years. One study found DAA therapy,
vs interferon-based therapy or antiviral therapy, was associated with
decreased risk of cardiovascular events, including acute myocar-
dial infarction, congestive heart failure, and stroke (incidence rate
per 1000 person-years of follow-up, 16.3 [95% CI, 14.7 to 18.0] for
DAA therapy; 23.5 [95% CI, 21.8 to 25.3] for interferon-based therapy;
and 30.4 [95% CI, 29.2 to 31.7] for no therapy; P < .001 for antiviral
therapy vs no therapy).67 One study found DAA and interferon-
based therapy associated with similar incidence of hepatocellular car-
cinoma that was lower than with no antiviral therapy (incidence rate
per 1000 person-years, 7.5 [95% CI, 6.5 to 8.6] and 7.9 [95% CI, 6.0
to 10.4] for antiviral therapy and 10.9 [95% CI, 9.92 to 11.97] for no
therapy; P value not reported).83 The third study found no differ-
ence between DAA therapy vs no antiviral therapy in risk of hepa-
tocellular carcinoma (adjusted HR, 1.02 [95% CI, 0.40 to 2.61]); point
estimates for associations with all-cause mortality favored DAA
therapy, but the difference was not statistically significant (ad-
justed HR, 0.74 [95% CI, 0.43 to 1.28]).68
Adolescents
Three treatment studies of adolescents (n = 200) reported changes
of 2 to 13 points on Pediatric Quality of Life Inventory (scale, 0-100)
scores after treatment with DAA therapy compared with baseline;
effects were not always statistically significant (eTable 3 in the
Supplement).59,61,100 Treatment studies of DAA therapy in adoles-
cents were not designed to evaluate mortality (no deaths in 3
studies)57,61,62 or long-term clinical outcomes.
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Key Question 7. What is the effectiveness of currently rec-
ommended antiviral treatments in achieving an SVR in patients
with HCV infection?
Adults
Forty-nine studies (in 44 publications; n = 10 181) reported effects of
current DAA treatment regimens on SVR in patients with HCV
infection.12-55 SVR was measured 12 weeks after the completion of
therapy in all studies except for 1, which measured SVR at 14 weeks.
Sample sizes ranged from 20 to 706, mean age ranged from 45 to 68
years, and the proportion of women ranged from 18% to 64%; the
studies evaluated 7 different antiviral regimens (eTable 4 in the Supple-
ment). One study was a randomized trial that compared a current DAA
regimen vs placebo,14 2 randomized trials (reported in 1 publication)
compared a current DAA regimen vs a regimen with telaprevir,12 and
2 randomized trials (reported in 1 publication) compared a current vs
older DAA regimen.15 The other treatment studies did not compare a
current DAA regimen vs placebo or an older regimen.
Thirteen studies were rated as good quality12-14,17,19,28,29,33,35,
36,46,51,54 and the remainder as fair quality (eTable 5 in the Supple-
ment). Methodological limitations included unclear randomization or
enrollment methods. Loss to follow-up was low (range, 0%-3%).
All of the trials were industry-funded.
SVR Rates in Comparative Trials | Few studies compared DAA inter-
ventions with placebo or older interventions (eTable 5 in the Supple-
ment). One randomized trial found sofosbuvir/velpatasvir associ-
ated with very high likelihood of SVR vs placebo in persons with mixed-
genotype (1, 2, 4, 5, or 6) infection (99% vs 0%; relative risk [RR], 231.6
[95% CI, 14.6 to 3680]).14 Two randomized trials found ombitasvir/
paritaprevir/ritonavir/dasabuvir (with or without ribavirin) associ-
ated with increased likelihood of SVR vs telaprevir/pegylated inter-
feron/ribavirin in treatment-naive persons with genotype 1 infection
(98% vs 80%; RR, 1.22 [95% CI, 1.08 to 1.37]) or persons previously
treated with interferon therapy (99% vs 66%; RR, 1.50 [95% CI, 1.22
to 1.85]).12 Two randomized trials found sofosbuvir/velpatasvir for 12
weeks associated with increased likelihood of SVR vs sofosbuvir/
ribavirin for 24 weeks for genotype 2 (99% vs 94%; RR, 1.06 [95%
CI, 1.01 to 1.11]) and for genotype 3 infection (noncirrhosis subgroup,
97% vs 87%; RR, 1.11 [95% CI, 1.05 to 1.18]).15
Pooled SVR Rates | For genotype 1 HCV infection, the most com-
mon genotype in the US, DAA therapy was associated with a pooled
SVR rate of 97.7% (95% CI, 96.6% to 98.4%; I2 = 82%) based on 32
studies (n = 6055) (Figure 3). Evidence for genotypes 2 through 6
was more limited, ranging from 75 to 742 participants per geno-
type (eTable 7 in the Supplement). The pooled SVR rates ranged from
95.5% to 98.9%; for other common US genotypes, the pooled SVR
was 98.9% (95% CI, 97.5% to 99.5%; I2 = 4%) for genotype 2 (5
studies, n = 526) (eFigure 1 in the Supplement), 95.5% (95% CI,
91.6% to 97.7%; I2 = 66%) for genotype 3 (6 studies, n = 742) (eFig-
ure 2 in the Supplement), and 98.2% (95% CI, 94.7% to 99.4%;
I2 = 50%) for genotype 4 (10 studies, n = 485) (eFigure 3 in the
Supplement). Across genotypes, SVR estimates were consistent
when studies were stratified according to study quality, geo-
graphic setting, prior HCV treatment, inclusion of some patients with
cirrhosis at baseline, and use of ribavirin as recommended (eTable 7
in the Supplement).
Adolescents
Seven studies (n = 348) evaluated the effects of DAA regimens on
SVR in adolescents (eTable 8 in the Supplement).56-62 Mean age
ranged from 12 to 15 years, and the proportion of female partici-
pants ranged from 35% to 66%. Three of the 7 studies were con-
ducted in Egypt and focused on genotype 4 infection, 1 study en-
rolled patients with genotype 1, and 3 studies enrolled mixed
genotypes. Four studies evaluated DAA regimens approved by the
US Food and Drug Administration (FDA) for use in adolescents,57-59,61
and the others evaluated DAA regimens recommended for adults
but not FDA-approved for adolescents.56,60,62 Across all interven-
tion studies of DAA in adolescents, the SVR rate ranged from 97%
to 100%.
Harms of Treatment
Key Question 8. What are the harms of currently recommended an-
tiviral treatments?
Adults
Forty-nine treatment studies (in 44 publications; n = 10 181) of DAA
regimens without interferon reported the proportion of patients who
experienced adverse events at short-term follow-up (ie, while tak-
ing antiviral therapy through up to 12 weeks after completion of
therapy).12-55
Adverse Events in Comparative Trials | Four randomized trials (total
n = 2113) reported adverse events associated with current DAA regi-
mens vs placebo (eTable 9 in the Supplement).13,14,16,17 DAA regi-
mens were associated with slightly increased risk of any adverse
event (4 trials; RR, 1.12 [95% CI, 1.02 to 1.24]; I2 = 46%; absolute risk
difference [ARD], 8% [95% CI, 8% to 15%]) (eTable 9 in the Supple-
ment). DAA therapy was also associated with increased risk of nau-
sea (3 trials; RR, 1.42 [95% CI, 1.00 to 2.03]; I2 = 10%; ARD, 4% [95%
CI, −3% to 10%]); the association with increased risk of diarrhea was
not statistically significant (2 trials; RR, 1.53 [95% CI, 0.88 to 2.68];
I2 = 29%). There were no differences between DAA regimens vs pla-
cebo in risk of serious adverse events, withdrawal due to adverse
events, headache, or fatigue.
Two randomized trials (reported in 1 publication; n = 457) com-
pared a DAA regimen (ombitasvir/paritaprevir/ritonavir/dasabuvir
with or without ribavirin) vs telaprevir/pegylated interferon/
ribavirin for genotype 1 infection (eTable 10 in the Supplement).12
DAA therapy was associated with decreased risk of serious adverse
events (RR, 0.08 [95% CI, 0.02 to 0.34]; I2 = 0%; ARD, −8% [95%
CI, −15% to −1%]) and withdrawal due to adverse events (RR, 0.06
[95% CI, 0.01 to 0.29]; I2 = 0%; ARD, −9% [95% CI, −14% to −3%])
vs the telaprevir regimen. DAA therapy was also associated with de-
creased risk of fatigue, headache, nausea, anemia, and rash (eTable 10
in the Supplement).
Pooled Adverse Event Rates for DAA Regimens | DAA therapy was fre-
quently associated with experiencing any adverse event (44 trials,
n = 8045; 73.3% [95% CI, 68.0% to 78.1%]; I2 = 95%) (eFigure 4
in the Supplement), though serious adverse events (44 studies,
n = 8070; 1.9% [95% CI, 1.5% to 2.4%]; I2 = 33%) (eFigure 5 in the
Supplement) and withdrawal due to adverse events (44 studies,
n = 8060; 0.4% [95% CI, 0.3% to 0.6%]; I2 = 0%) (eFigure 6 in the
Supplement) were infrequent (eTable 11 in the Supplement). Pooled
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Figure 3. Direct-Acting Antiviral Regimens and Pooled Sustained Virologic Response Rates in People With Genotype 1 Hepatitis C Virus Infection
0 .75 1.5
Effect size (95% CI)
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Country Age, y Women, %
Fibrosis stage
(% cirrhosis)
Treatment
naive
Events/
totalSource
Ledipasvir/sofosbuvir
Effect size (95% CI)
Heterogeneity between groups: P = .005
Overall: I2 = 81.6%, P <.001
Multinational 52 41 0 Yes 357/357Afdhal et al,35 2014 1.000 (0.990-1.000)
US 53 40 0 Yes 408/431Kowdley et al,35 2014 0.947 (0.921-0.966)
US 48 38 0 Yes 58/60Lawitz et al,40 2014 0.967 (0.885-0.996)
Simeprevir/sofosbuvir
US 56 29 0 Mixed 61/64Lawitz et al,39 2014 0.953 (0.869-0.990)
Canada and US 56 47 0 Mixed 150/155Kwo et al,37 2016 0.968 (0.926-0.989)
Brazil 53 48 0 Mixed 56/60Pott-Junior et al,46 2019 0.933 (0.838-0.982)
Taiwan 55 58 ≤20 Mixed 83/85Chuang et al,27 2016 0.976 (0.918-0.997)
Korea 54 61 ≤20 Yes 46/46Lim et al,42 2016 1.000 (0.923-1.000)
China 47 50 ≤20 No 206/206Wei et al,53 2018 1.000 (0.982-1.000)
Elbasvir/grazoprevir
Multinational 51 51 0 Yes 122/129Sulkowski et al,49 2015 0.946 (0.891-0.978)
Multinational 52 46 ≤20 Yes 273/288Zeuzem et al,54 2015 0.948 (0.916-0.971)
Multinational 48 57 ≤20 Mixed 122/123Sperl et al,47 2016 0.992 (0.956-1.000)
Ng et al,99 2018
Japan 61 62 0 Mixed 219/227Kumada et al,36 2017 0.965 (0.932-0.985)
Ombitasvir/paritaprevir/ritonavir/dasabuvir (genotype 1a)
Multinational 49 43 Unclear/NR Yes 307/322Feld et al,13 2014 0.953 (0.924-0.974)
Multinational 51 35 0 Yes 282/305Ferenci et al,29 2014 0.925 (0.889-0.952)
Multinational 50 42 0 Mixed 183/212Kowdley et al,34 2014 0.863 (0.809-0.906)
Multinational 46 39 0 Mixed 67/69Dore et al,12 2016a 0.971 (0.899-0.996)
Multinational 47 46 0 Mixed 19/19Dore et al,12 2016b 1.000 (0.824-1.000)
Ombitasvir/paritaprevir/ritonavir/dasabuvir (genotype 1b)
Multinational 54 46 0 No 176/179Andreone et al,22 2014 0.983 (0.952-0.997)
Multinational 49 43 Unclear/NR Yes 148/151Feld et al,13 2014 0.980 (0.943-0.996)
Multinational 48 54 0 Yes 416/419Ferenci et al,29 2014 0.993 (0.979-0.999)
Multinational 50 47 0 Mixed 113/113Kowdley et al,34 2014 1.000 (0.968-1.000)
Japan 61 63 0 Mixed 204/215Kumada et al,16 2015 0.949 (0.910-0.974)
Multinational 55 51 0 Mixed 76/82Lawitz et al,41 2015 0.927 (0.848-0.973)
Multinational 46 54 0 Mixed 164/167Dore et al,12 2016a 0.982 (0.948-0.996)
Multinational 47 46 0 Mixed 81/82Dore et al,12 2016b 0.988 (0.934-1.000)
Multinational 48 56 ≤20 Yes 422/432Wei et al,53 2019 0.977 (0.958-0.989)
Subtotal: I2 = 88.7%, P <.001 0.994 (0.952-0.999)
Subtotal: I2 = 0.0%, P = .50 0.957 (0.926-0.975)
Sofosbuvir/velpatasvir
US 49 39 0 Yes 28/28Everson et al,28 2015 1.000 (0.877-1.000)
Multinational 54 40 0 Mixed 251/255Feld et al,14 2015 0.984 (0.960-0.996)
Sofosbuvir/daclatasvir
US 55 50 ≤20 Yes 80/82Sulkowski et al,48 2014 0.976 (0.915-0.997)
Brazil 56 52 00 Mixed 65/65Pott-Junior et al,46 2019 1.000 (0.945-1.000)
Multinational 45 47 ≤20 No 129/129Wei et al,17 2019 1.000 (0.972-1.000)
Subtotal: I2 = 26.6%, P = .26 0.990 (0.954-0.998)
Glecaprevir/pibrentasvir
US 58 18 00 No 46/50Poordad et al,45 2017 0.920 (0.808-0.978)
Japan 64 64 Unclear/NR Mixed 128/129Chayama et al,26 2018 0.992 (0.958-1.000)
Multinational 53 51 00 No 663/667Zeuzem et al,55 2018 0.994 (0.985-0.998)
Subtotal: I2 = 77.9%, P = .01 0.986 (0.941-0.997)
Subtotal: I2 = 54.6%, P = .07 0.967 (0.950-0.978)
Subtotal: I2 = 45.3%, P = .18 0.986 (0.947-0.997)
Ombitasvir/paritaprevir/ritonavir/dasabuvir
US 48 34 0 Mixed 37/38Lalezari et al,38 2015 0.974 (0.862-0.999)
Multinational 48 23 0 Yes 73/80Grebely et al,32 2018 0.913 (0.828-0.964)
Subtotal: I2 = 26.7%, P = .24 0.932 (0.870-0.966)
Subtotal: I2 = 77.2%, P = .002 0.937 (0.890-0.965)
Subtotal: I2 = 68.5%, P = .002 0.982 (0.964-0.991)
0.977 (0.966-0.984)
The area of each square represents each pooled estimate (subgroup or overall
analysis), and the width of each diamond represents the confidence interval for
the pooled estimate. The dashed line indicates the overall measure of effect.
SVR indicates sustained virologic response.
a Treatment-naive.
b Treatment-experienced.
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rates for specific adverse events ranged from 2.4% (anemia) to 18.7%
(headache) (eTables 12 and 13 in the Supplement). There was some
variability by DAA regimen in estimates of adverse events; esti-
mates were generally higher for ombitasvir/paritaprevir/ritonavir/
dasabuvir with ribavirin than without ribavirin (eTables 11-13 in the
Supplement). Adverse event estimates were generally similar when
studies were stratified according to baseline cirrhosis status and prior
antiviral therapy experience.
Adolescents
Seven treatment studies (n = 348) of DAA regimens in adolescents
reported harms, but methods for reporting and assessing harms were
generally not well described (eTable 14 in the Supplement).56-62
Rates of any adverse event were 27% in 1 study62 and ranged from
71% to 87% in 4 studies.57,59-61 There were no withdrawals due to
adverse events reported in 5 studies,57,59-62 and 1 study61 reported
1 serious adverse event (a grade 3 joint injury). Rates of other ad-
verse events were highly variable. For example, 3% to 48% of study
participants reported headache. Stratification according to DAA regi-
men did not explain the observed variability.
SVR and Health Outcomes
Key Question 9. What is the association between experiencing SVR
following antiviral treatment and reduction in risk of HCV-related ad-
verse health outcomes?
Thirty cohort studies reported associations between achieving
SVRafterantiviraltreatmentvsnoSVRandclinicaloutcomes(eTable15
in the Supplement).63-66,68-82,84-94 Sample sizes ranged from 131 to
50 886 (total n = 116 659), mean age ranged from 42 to 69 years, and
the proportion of women ranged from 1% to 56%. Seventeen stud-
ies were conducted in Japan (including some with overlapping
populations),63,64,71,73-75,78-81,84-86,89,90,92,93 4 in other Asian
countries,82,88,91,94 7 in the US (all except for 187 conducted in Veter-
ans Affairs populations),65,66,69,70,72,77,87 and 2 in Europe.68,76 When
genotype was reported, genotype 1 was generally the most common
(36%-89%) and genotype 2 the second most common (6%-52%).
Mean follow-up ranged from 1.5 to 10 years in all studies except for 1
study that described follow-up of at least 1 year.88 Twenty-six stud-
ies evaluated interferon-based therapies. Three studies focused on
DAAs,66,68,77 1 study evaluated interferon-based treatments and
DAAs,77 and 1 study did not report what type of treatment was ad-
ministered (likely primarily interferon-based therapies).72 All studies
were rated fair quality (eTable 16 in the Supplement).
SVR was associated with significantly decreased risk of all-cause
mortality (13 studies, n = 36 986; HR, 0.40 [95% CI, 0.28 to 0.56];
I2 = 52%) (Figure 4).63,65,66,68-70,75,76,80,84,87,93,94 Studies with lon-
ger duration of follow-up (>5 years) reported a stronger association
between SVR after antiviral therapy and reduced risk of all-cause mor-
tality (pooled HR, 0.33 [95% CI, 0.24 to 0.46]) than those with shorter
follow-up (pooled HR, 0.64 [95% CI, 0.56 to 0.74]) (P = .003 for in-
teraction). SVR was also associated with decreased risk of hepatocel-
lular carcinoma (20 studies, n = 84 491; pooled HR, 0.29 [95% CI, 0.23
to 0.38]; I2 = 19%) (Figure 4),63,64,68,70-74,77-79,81,82,84-86,89,90,92,94
liver-related mortality (4 studies, n = 5953; pooled HR, 0.11 [95% CI,
0.04 to 0.27]; I2 = 0%) (eFigure 7 in the Supplement),63,75,80,93 and
cirrhosis (4 cohorts reported in 3 studies, n = 16 735; pooled HR, 0.36
[95% CI, 0.33 to 0.40]; I2 = 0%) (eFigure 8 in the Supplement).69,72,91
There were no statistically significant interactions when studies were
stratified according to how well they adjusted for key confounders,
duration of follow-up, country/setting, or the proportion of partici-
pants with cirrhosis at baseline (eTable 15 in the Supplement). Re-
sults were also similar when studies with potentially overlapping popu-
lations were excluded.
Discussion
The findings in this evidence report are summarized in the Table.
Since the prior USPSTF recommendation, there has been a major
shift in antiviral therapy to all-oral DAA regimens without inter-
feron. New pooled evidence indicates that SVR rates with cur-
rently recommended all-oral DAA regimens are substantially higher
(>95%) than with interferon-based therapies evaluated in the prior
review (68%-78%).9 Although statistical heterogeneity was pre-
sent in pooled estimates of SVR rates, findings were robust when
studies were stratified according to the DAA regimen evaluated,
study quality, prior treatment status, and cirrhosis status. Few ran-
domized trials directly compared a current DAA regimen vs pla-
cebo or an older antiviral regimen, but those available also found DAA
therapy associated with greater effectiveness. DAA regimens were
associated with fewer harms than older interferon-containing thera-
pies. Evidence on DAA therapies in adolescents was limited, but con-
sistently reported high (97%-100%) SVR rates.
Direct evidence on the effects of antiviral therapy on clinical out-
comes is limited. Although several randomized trials found inter-
feron therapy associated with decreased risk of hepatocellular car-
cinoma compared with no antiviral therapy, they did not meet
inclusion criteria for this report because they focused on patients
with cirrhosis at baseline or used a nonstandard regimen.101-108 Stud-
ies of DAA therapies were not designed to assess effects on mor-
tality or other long-term clinical outcomes. There were few cohort
studies of antiviral therapy vs no therapy, results were somewhat
inconsistent, and findings were susceptible to residual confound-
ing. Given the limited direct evidence on the effects of antiviral
therapy on clinical outcomes, cohort studies of the association be-
tween SVR after antiviral therapy vs no SVR and clinical outcomes
may help to understand potential clinical effects of DAA therapy. As
in the prior USPSTF review, there was a consistent association be-
tween SVR after antiviral therapy and improved clinical outcomes,
including mortality and hepatocellular carcinoma.9
The findings in this evidence report regarding the benefits and
harms of current DAA regimens were consistent with a recent sys-
tematic review that also reported high (>95%) SVR rates in geno-
type 1 infection without cirrhosis, high SVR rates but more limited
evidence for other HCV genotypes, low rates of serious adverse
events and treatment discontinuation, and higher adverse event
rates with ribavirin.109 The results are also consistent with a sys-
tematic review that found insufficient evidence from clinical trials
to determine effects of DAA regimens on HCV-related mortality and
morbidity110; unlike that review, this one also evaluated the indi-
rect chain of evidence linking DAA therapy with SVR, and SVR with
clinical outcomes. This review is consistent with prior reviews that
found a consistent association between an SVR after antiviral therapy
and reduced risk of mortality and hepatocellular carcinoma.111-113
Research is needed to better understand the association be-
tween use of current DAA therapy and clinical outcomes. Long-term
USPSTF Report: Screening for Hepatitis C Virus Infection in Adolescents and Adults US Preventive Services Task Force Clinical Review & Education
jama.com (Reprinted) JAMA March 10, 2020 Volume 323, Number 10 983
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Portland State University User  on 04/13/2020
Fi
gu
re
4.
As
so
ci
at
io
n
of
Su
st
ai
ne
d
Vi
ro
lo
gi
cR
es
po
ns
e
W
ith
Cl
in
ic
al
O
ut
co
m
es
Du
ra
tio
n,
 y
Co
un
tr
y
Re
st
ric
te
d 
to
 F
0-
F1
Ci
rr
ho
si
s,
 %
Tr
ea
tm
en
t
Ad
ju
st
m
en
t
%
 G
en
ot
yp
e 
1
SV
R/
no
 S
VR
So
ur
ce
H
az
ar
d 
ra
tio
 (9
5%
 C
I)
5.
4
As
ia
N
o
0-
10
In
te
rf
er
on
Pa
rt
ia
l
N
R
81
7/
16
13
Yo
sh
id
a 
et
 a
l,9
3  
20
02
0.
32
 (0
.1
2-
0.
86
)
8.
2
As
ia
N
o
>1
0
In
te
rf
er
on
Pa
rt
ia
l
74
11
6/
23
9
Im
az
ek
i e
t a
l,7
5  
20
03
0.
35
 (0
.0
9-
1.
36
)
5.
7
As
ia
N
o
>1
0
In
te
rf
er
on
Pa
rt
ia
l
N
R
73
8/
19
30
Ka
sa
ha
ra
 e
t a
l,8
0  
20
04
0.
24
 (0
.0
8-
0.
68
)
5.
2
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
46
71
5/
34
2
Yu
 e
t a
l,9
4  
20
06
0.
28
 (0
.0
8-
1.
02
)
7.
4
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
60
14
0/
36
0
Ar
as
e 
et
 a
l,6
3  
20
07
0.
39
 (0
.1
6-
0.
93
)
3.
8
US
N
o
>1
0
In
te
rf
er
on
Fu
ll
72
74
34
/9
43
0
Ba
ck
us
 e
t a
l,6
5  
20
11
0.
66
 (0
.5
7-
0.
76
)
5.
3
Eu
ro
pe
N
o
>1
0
In
te
rf
er
on
Fu
ll
36
56
0/
65
5
In
ne
s e
t a
l,7
6  
20
11
0.
22
 (0
.0
9-
0.
58
)
9.
9
As
ia
N
o
0-
10
In
te
rf
er
on
Fu
ll
73
22
1/
35
6
M
ar
uo
ka
 e
t a
l,8
4  
20
12
0.
20
 (0
.0
8-
0.
54
)
10
.0
US
N
o
0-
10
In
te
rf
er
on
Fu
ll
61
69
/7
1
Co
ze
n 
et
 a
l,6
9  
20
13
0.
50
 (0
.1
2-
2.
10
)
5.
0
US
N
o
>1
0
In
te
rf
er
on
Fu
ll
68
83
/1
59
Si
ng
al
 e
t a
l,8
7  
20
13
0.
11
 (0
.0
3-
0.
47
)
7.
5
US
N
o
>1
0
In
te
rf
er
on
Fu
ll
70
22
2/
31
4
Di
ep
er
in
k 
et
 a
l,7
0  
20
14
0.
47
 (0
.2
6-
0.
85
)
1.
5
US
Ye
s
>1
0
DA
A
Fu
ll
85
63
71
/5
99
Bu
tt
 e
t a
l,6
6  
20
17
0.
57
 (0
.3
3-
0.
99
)
2.
8
Eu
ro
pe
N
o
0-
10
DA
A
Fu
ll
67
32
86
/1
46
Ca
rr
at
 e
t a
l,6
8  
20
19
1.
36
 (0
.1
5-
12
.3
5)
O
ve
ra
ll:
 I2
 =
 5
2.
1%
, P
 =
 .0
2
0.
40
 (0
.2
8-
0.
56
)
SV
R 
vs
 n
o 
SV
R:
 a
ll-
ca
us
e 
m
or
ta
lit
y
A
Fa
vo
rs
 S
VR
Fa
vo
rs
 N
o 
SV
R
H
az
ar
d 
ra
tio
 (9
5%
 C
I)
Du
ra
tio
n,
 y
Co
un
tr
y
Re
st
ric
te
d 
to
 F
0-
F1
Ci
rr
ho
si
s,
 %
Tr
ea
tm
en
t
Ad
ju
st
m
en
t
%
 G
en
ot
yp
e 
1
SV
R/
no
 S
VR
So
ur
ce
H
az
ar
d 
ra
tio
 (9
5%
 C
I)
4.
0
As
ia
N
o
0-
10
In
te
rf
er
on
Pa
rt
ia
l
N
R
15
1/
26
8
Im
ai
 e
t a
l,7
4  
19
99
0.
06
 (0
.0
1-
0.
48
)
3.
1
As
ia
N
o
0-
10
In
te
rf
er
on
Fu
ll
58
31
3/
40
5
Ka
sa
ha
ra
 e
t a
l,7
9  
19
98
0.
19
 (0
.0
6-
0.
58
)
5.
4
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
67
60
6/
58
5
Ik
ed
a 
et
 a
l,7
3  
19
99
0.
33
 (0
.1
2-
0.
96
)
4.
3
As
ia
N
o
0-
10
In
te
rf
er
on
Pa
rt
ia
l
70
78
9/
15
68
Yo
sh
id
a 
et
 a
l,9
2  
19
99
0.
32
 (0
.1
4-
0.
70
)
4.
8
As
ia
N
o
0-
10
In
te
rf
er
on
Fu
ll
75
17
5/
41
9
Ta
na
ka
 e
t a
l,8
9  
20
00
0.
29
 (0
.0
7-
1.
28
)
5.
6
As
ia
N
o
0-
10
In
te
rf
er
on
Pa
rt
ia
l
N
R
42
6/
35
8
O
ka
no
ue
 e
t a
l,8
5  
20
02
0.
13
 (0
.0
6-
0.
27
)
As
ia
N
o
0-
10
In
te
rf
er
on
Un
cl
ea
r
50
15
5/
34
0
Iz
um
i e
t a
l,7
8  
20
05
0.
36
 (0
.0
4-
0.
83
)
5.
2
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
46
71
5/
34
2
Yu
 e
t a
l,9
4  
20
06
0.
24
 (0
.1
1-
0.
52
)
7.
4
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
60
14
0/
36
0
Ar
as
e 
et
 a
l,6
3  
20
07
0.
19
 (0
.0
8-
0.
45
)
3.
0
As
ia
N
o
0-
10
In
te
rf
er
on
Pa
rt
ia
l
73
13
9/
26
4
Ku
ro
ka
w
a 
et
 a
l,8
1  
20
09
0.
28
 (0
.0
8-
0.
96
)
7.
5
As
ia
N
o
0-
10
In
te
rf
er
on
Fu
ll
70
68
6/
13
56
As
ah
in
a 
et
 a
l,6
4  
20
10
0.
38
 (0
.1
8-
0.
83
)
8.
2
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
72
13
9/
23
4
Ta
te
ya
m
a 
et
 a
l,9
0  
20
11
0.
14
 (0
.0
4-
0.
52
)
9.
9
As
ia
N
o
0-
10
In
te
rf
er
on
Fu
ll
73
22
1/
35
6
M
ar
uo
ka
 e
t a
l,8
4  
20
12
0.
12
 (0
.0
3-
0.
41
)
4.
1
As
ia
N
o
0-
10
In
te
rf
er
on
Pa
rt
ia
l
60
18
5/
19
7
O
sa
ki
 e
t a
l,8
6  
20
12
0.
12
 (0
.0
1-
0.
94
)
4.
8
As
ia
N
o
N
R/
un
cl
ea
r
In
te
rf
er
on
Pa
rt
ia
l
67
28
5/
18
9
Do
hm
en
 e
t a
l,7
1  
20
13
0.
39
 (0
.3
2-
0.
48
)
7.
5
US
N
o
>1
0
In
te
rf
er
on
Fu
ll
70
22
2/
31
4
Di
ep
er
in
k 
et
 a
l,7
0  
20
14
0.
41
 (0
.1
8-
0.
96
)
5.
2
US
N
R/
un
cl
ea
r
N
R/
un
cl
ea
r
N
R
Fu
ll
55
75
77
/8
76
7
El
-S
er
ag
 e
t a
l,7
2  
20
14
0.
30
 (0
.2
3-
0.
38
)
2.
6
As
ia
N
o
>1
0
In
te
rf
er
on
Fu
ll
51
30
6/
18
3
Le
e 
et
 a
l,8
2  
20
17
0.
09
 (0
.0
2-
0.
40
)
6.
1
US
N
o
>1
0
M
ix
ed
Fu
ll
77
28
 6
55
/2
3 
23
1
Io
an
no
u 
et
 a
l,7
7  
20
18
0.
32
 (0
.2
8-
0.
37
)
2.
8
Eu
ro
pe
N
o
0-
10
DA
A
Fu
ll
67
32
86
/1
46
Ca
rr
at
 e
t a
l,6
8  
20
19
0.
22
 (0
.0
3-
1.
76
)
O
ve
ra
ll:
 I2
 =
 1
8.
7%
, P
 =
 .2
2
0.
29
 (0
.2
3-
0.
38
)
SV
R 
vs
 n
o 
SV
R:
 h
ep
at
oc
el
lu
la
r c
ar
ci
no
m
a
B
Fa
vo
rs
 S
VR
Fa
vo
rs
 N
o 
SV
R
1
4
0.
1
0.
06
H
az
ar
d 
ra
tio
 (9
5%
 C
I)
0.
02
1
0.
1
4
Th
e
ar
ea
of
ea
ch
sq
ua
re
re
pr
es
en
ts
ea
ch
po
ol
ed
es
tim
at
e
(s
ub
gr
ou
p
or
ov
er
al
la
na
ly
sis
),
an
d
th
e
w
id
th
of
ea
ch
di
am
on
d
re
pr
es
en
ts
th
e
co
nf
id
en
ce
in
te
rv
al
fo
rt
he
po
ol
ed
es
tim
at
e.
D
as
he
d
lin
es
in
di
ca
te
th
e
ov
er
al
lm
ea
su
re
so
f
ef
fe
ct
;o
ve
ra
lle
st
im
at
es
w
er
e
fr
om
m
ix
ed
-e
ffe
ct
sm
od
el
s.
DA
A
in
di
ca
te
sd
ire
ct
-a
ct
in
g
an
tiv
ira
l;
IF
N
,i
nt
er
fe
ro
n;
N
R,
no
tr
ep
or
te
d;
SV
R,
su
st
ai
ne
d
vi
ro
lo
gi
cr
es
po
ns
e.
Clinical Review & Education US Preventive Services Task Force USPSTF Report: Screening for Hepatitis C Virus Infection in Adolescents and Adults
984 JAMA March 10, 2020 Volume 323, Number 10 (Reprinted) jama.com
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Portland State University User  on 04/13/2020
Ta
bl
e.
Su
m
m
ar
y
of
Ev
id
en
ce
St
ud
y
de
si
gn
Su
m
m
ar
y
of
fin
di
ng
s
Co
ns
is
te
nc
y
an
d
pr
ec
is
io
n
O
ve
ra
ll
qu
al
ity
Bo
dy
of
ev
id
en
ce
lim
ita
tio
ns
EP
C
as
se
ss
m
en
t
of
st
re
ng
th
of
ev
id
en
ce
fo
rK
Q
Ap
pl
ic
ab
ili
ty
KQ
1:
Be
ne
fit
so
fs
cr
ee
ni
ng
N
o
st
ud
ie
s
N
A
N
A
N
A
N
A
N
A
N
A
KQ
2:
Sc
re
en
in
g
st
ra
te
gi
es
N
o
st
ud
ie
s
N
A
N
A
N
A
N
A
N
A
N
A
KQ
3:
Sc
re
en
in
g
st
ra
te
gi
es
an
d
yi
el
d
Pr
io
rr
ev
ie
w
:5
st
ud
ie
s(
4
cr
os
s-
se
ct
io
na
ls
tu
di
es
[n
=
76
15
]a
nd
1
ca
se
-c
on
tr
ol
st
ud
y
[n
=
42
9]
)
N
ew
ev
id
en
ce
:1
re
tr
os
pe
ct
iv
e
st
ud
y
ev
al
ua
tin
g
sc
re
en
in
g
yi
el
d
(n
=
59
17
)
Th
e
pr
io
rr
ev
ie
w
in
cl
ud
ed
5
st
ud
ie
st
ha
tf
ou
nd
ris
k-
ba
se
d
sc
re
en
in
g
as
so
ci
at
ed
w
ith
se
ns
iti
vi
tie
so
f>
90
%
an
d
N
N
Ss
<2
0
to
id
en
tif
y
1
ca
se
of
H
CV
in
fe
ct
io
n
O
ne
ne
w
st
ud
y
fo
un
d
th
at
pe
rf
ec
ta
pp
lic
at
io
n
of
ris
k-
ba
se
d
gu
id
el
in
es
w
ou
ld
id
en
tif
y
82
%
of
H
CV
ca
se
sw
ith
an
N
N
S
of
14
.6
to
id
en
tif
y
1
ca
se
of
H
CV
in
fe
ct
io
n,
w
hi
le
ap
pl
yi
ng
a
bi
rt
h
co
ho
rt
st
ra
te
gy
w
ou
ld
re
su
lt
in
76
%
of
ca
se
si
de
nt
ifi
ed
w
ith
an
N
N
S
of
28
.7
Re
as
on
ab
ly
co
ns
is
te
nt
an
d
pr
ec
is
e
Fa
ir
St
ud
ie
sw
er
e
re
tr
os
pe
ct
iv
e,
an
d
in
so
m
e
st
ud
ie
ss
ig
ni
fic
an
tp
ro
po
rt
io
ns
of
pa
tie
nt
sw
er
e
no
tt
es
te
d
N
o
st
ud
ie
so
ft
he
yi
el
d
of
1-
tim
e
vs
re
pe
at
sc
re
en
in
g,
al
te
rn
at
iv
e
sc
re
en
in
g
st
ra
te
gi
es
in
di
ff
er
en
tr
is
k
gr
ou
ps
,o
rt
he
yi
el
d
of
cu
rr
en
tly
re
co
m
m
en
de
d
sc
re
en
in
g
vs
ex
pa
nd
ed
sc
re
en
in
g
st
ra
te
gi
es
Lo
w
M
os
ts
tu
di
es
co
nd
uc
te
d
in
hi
gh
-p
re
va
le
nc
e
se
tt
in
gs
O
ne
st
ud
y
as
su
m
ed
pe
rf
ec
ta
pp
lic
at
io
n
of
ris
k-
ba
se
d
sc
re
en
in
g,
w
hi
ch
ha
sn
ot
be
en
at
ta
in
ab
le
KQ
4:
H
ar
m
so
fs
cr
ee
ni
ng
Pr
io
rr
ev
ie
w
:5
st
ud
ie
s(
1
cr
os
s-
se
ct
io
na
ls
tu
dy
[n
=
34
],
3
in
te
rv
en
tio
n
se
rie
ss
tu
di
es
[n
=
22
0]
,1
co
nt
ro
lle
d
tr
ia
l
[n
=
34
])
N
ew
ev
id
en
ce
:n
o
ne
w
st
ud
ie
s
Po
or
-q
ua
lit
y
ev
id
en
ce
fr
om
th
e
pr
io
rr
ev
ie
w
su
gg
es
te
d
po
te
nt
ia
l
ne
ga
tiv
e
ps
yc
ho
lo
gi
ca
la
nd
so
ci
al
ef
fe
ct
so
fs
cr
ee
ni
ng
;t
he
se
st
ud
ie
s
di
d
no
tm
ee
ti
nc
lu
si
on
cr
ite
ria
fo
rt
hi
su
pd
at
e
N
o
ne
w
st
ud
ie
so
n
ha
rm
so
fs
cr
ee
ni
ng
m
ee
tin
g
in
cl
us
io
n
cr
ite
ria
w
er
e
id
en
tif
ie
d
Lo
w
co
ns
is
te
nc
y
an
d
pr
ec
is
io
n
Po
or
Sm
al
ls
am
pl
e
si
ze
s,
no
un
sc
re
en
ed
co
m
pa
ris
on
gr
ou
p,
re
lia
nc
e
on
re
tr
os
pe
ct
iv
e
re
ca
ll,
po
or
ly
de
fin
ed
ou
tc
om
es
Lo
w
St
ud
ie
sw
er
e
co
nd
uc
te
d
in
th
e
er
a
of
in
te
rf
er
on
-b
as
ed
tr
ea
tm
en
ts
KQ
6:
Ef
fe
ct
of
tr
ea
tm
en
to
n
he
al
th
ou
tc
om
es
—
ad
ul
ts
Pr
io
rr
ev
ie
w
:N
A
(o
ut
da
te
d
re
gi
m
en
s)
N
ew
ev
id
en
ce
:3
7
st
ud
ie
s(
34
tr
ea
tm
en
ts
tu
di
es
[n
=
44
34
],
2
po
ol
ed
an
al
ys
es
[n
=
27
06
],
3
ob
se
rv
at
io
na
ls
tu
di
es
[n
=
58
89
2]
)
Tw
o
po
ol
ed
an
al
ys
es
of
3
an
d
4
st
ud
ie
se
ac
h
an
d
da
ta
fr
om
3
ot
he
r
st
ud
ie
sn
ot
in
cl
ud
ed
in
po
ol
ed
an
al
ys
es
fo
un
d
sm
al
l,
sh
or
t-
te
rm
im
pr
ov
em
en
ts
in
qu
al
ity
of
lif
e
sc
al
e
sc
or
es
af
te
rD
AA
th
er
ap
y
co
m
pa
re
d
w
ith
be
fo
re
In
31
DA
A
th
er
ap
y
st
ud
ie
sr
ep
or
tin
g
sh
or
t-
te
rm
(<
1
y)
m
or
ta
lit
y,
th
er
e
w
er
e
no
de
at
hs
in
21
st
ud
ie
s;
m
or
ta
lit
y
w
as
lo
w
in
th
e
re
m
ai
ni
ng
10
st
ud
ie
s(
0.
4%
[1
7/
38
48
]o
ve
ra
ll)
Tw
o
la
rg
e
ob
se
rv
at
io
na
ls
tu
di
es
fo
un
d
us
e
of
bo
th
DA
A
re
gi
m
en
s
as
so
ci
at
ed
w
ith
lo
w
er
ra
te
so
fc
ar
di
ov
as
cu
la
re
ve
nt
sa
nd
he
pa
to
ce
llu
la
rc
an
ce
r;
th
es
e
as
so
ci
at
io
ns
w
er
e
no
tf
ou
nd
in
a
th
ird
,
sm
al
le
ro
bs
er
va
tio
na
ls
tu
dy
w
ith
sh
or
te
rd
ur
at
io
n
of
fo
llo
w
-u
p
Co
ns
is
te
nt
;
im
pr
ec
is
e
Fa
ir
St
ud
ie
sr
ep
or
tin
g
qu
al
ity
of
lif
e
an
d
fu
nc
tio
n
w
er
e
no
tr
an
do
m
iz
ed
,u
se
d
an
op
en
-l
ab
el
de
si
gn
,a
nd
di
d
no
t
ha
ve
a
no
n-
DA
A
co
m
pa
ris
on
gr
ou
p
St
ud
ie
sp
ro
vi
de
d
sh
or
t-
te
rm
fo
llo
w
-u
p
an
d
w
er
e
no
td
es
ig
ne
d
to
as
se
ss
he
al
th
ou
tc
om
es
Ev
en
tr
at
es
fo
rm
or
ta
lit
y
w
er
e
lo
w
ac
ro
ss
st
ud
ie
s,
an
d
ot
he
rh
ea
lth
ou
tc
om
es
w
er
e
no
tw
id
el
y
re
po
rt
ed
Ev
id
en
ce
on
lo
ng
-t
er
m
cl
in
ic
al
ou
tc
om
es
w
as
lim
ite
d
to
3
ob
se
rv
at
io
na
ls
tu
di
es
Lo
w
St
ud
ie
sd
id
no
te
nr
ol
la
hi
gh
pr
op
or
tio
n
of
pa
tie
nt
sw
ith
ci
rr
ho
si
sa
tb
as
el
in
e
an
d
ev
al
ua
te
d
cu
rr
en
tD
AA
re
gi
m
en
s
Ev
id
en
ce
on
ef
fe
ct
so
n
he
pa
to
ce
llu
la
r
ca
nc
er
an
d
ca
rd
io
va
sc
ul
ar
ev
en
ts
w
as
pr
im
ar
ily
de
riv
ed
fr
om
a
VA
da
ta
ba
se
th
at
in
cl
ud
ed
fe
w
fe
m
al
e
in
di
vi
du
al
s
(3
%
-4
%
)
KQ
6:
Ef
fe
ct
of
tr
ea
tm
en
to
n
he
al
th
ou
tc
om
es
—
ad
ol
es
ce
nt
s
3
Tr
ea
tm
en
ts
tu
di
es
in
5
pu
bl
ic
at
io
ns
(n
=
23
0)
Th
er
e
w
er
e
no
de
at
hs
in
3
st
ud
ie
so
fD
AA
re
gi
m
en
sr
ep
or
tin
g
sh
or
t-
te
rm
m
or
ta
lit
y
So
fo
sb
uv
ir
w
ith
le
di
pa
sv
ir
or
rib
av
iri
n
an
d
gl
ec
ap
re
vi
rw
ith
pi
br
en
ta
sv
ir
w
er
e
as
so
ci
at
ed
w
ith
sm
al
li
m
pr
ov
em
en
ts
in
Pe
di
at
ric
Q
ua
lit
y
of
Li
fe
In
ve
nt
or
y
sc
or
es
co
m
pa
re
d
w
ith
ba
se
lin
e
Co
ul
d
no
tb
e
de
te
rm
in
ed
(f
or
qu
al
ity
of
lif
e)
;i
m
pr
ec
is
e
Fa
ir
St
ud
ie
sw
er
e
no
td
es
ig
ne
d
to
as
se
ss
lo
ng
-t
er
m
he
al
th
ou
tc
om
es
Th
e
on
ly
ev
id
en
ce
on
qu
al
ity
of
lif
e
ou
tc
om
es
is
ba
se
d
on
a
po
st
ho
c
an
al
ys
is
of
st
ud
y
da
ta
Lo
w
O
ne
st
ud
y
ev
al
ua
te
d
a
DA
A
re
gi
m
en
no
t
FD
A-
ap
pr
ov
ed
fo
ru
se
in
ad
ol
es
ce
nt
s
(c
on
tin
ue
d)
USPSTF Report: Screening for Hepatitis C Virus Infection in Adolescents and Adults US Preventive Services Task Force Clinical Review & Education
jama.com (Reprinted) JAMA March 10, 2020 Volume 323, Number 10 985
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Portland State University User  on 04/13/2020
Ta
bl
e.
Su
m
m
ar
y
of
Ev
id
en
ce
(c
on
tin
ue
d)
St
ud
y
de
si
gn
Su
m
m
ar
y
of
fin
di
ng
s
Co
ns
is
te
nc
y
an
d
pr
ec
is
io
n
O
ve
ra
ll
qu
al
ity
Bo
dy
of
ev
id
en
ce
lim
ita
tio
ns
EP
C
as
se
ss
m
en
t
of
st
re
ng
th
of
ev
id
en
ce
fo
rK
Q
Ap
pl
ic
ab
ili
ty
KQ
7:
Ef
fe
ct
of
tr
ea
tm
en
to
n
SV
R—
ad
ul
ts
Pr
io
rr
ev
ie
w
:N
A
(o
ut
da
te
d
re
gi
m
en
s)
N
ew
ev
id
en
ce
:4
9
st
ud
ie
s(
8
RC
Ts
an
d
41
no
nr
an
do
m
iz
ed
tr
ea
tm
en
ts
tu
di
es
;
n
=
10
18
1)
DA
A
vs
pl
ac
eb
o
(1
RC
T)
:S
VR
,9
9%
vs
0%
;R
R,
23
1.
6
(9
5%
CI
,
14
.6
-3
68
0)
DA
A
vs
te
la
pr
ev
ir
(2
RC
Ts
):
SV
R,
98
%
vs
80
%
;R
R,
1.
22
(9
5%
CI
,
1.
09
-1
.3
7)
an
d
99
%
vs
66
%
;R
R,
1.
50
(9
5%
CI
,1
.2
2-
1.
85
)
In
49
tr
ea
tm
en
ts
tu
di
es
,S
VR
ra
te
sw
ith
DA
A
th
er
ap
ie
sr
an
ge
d
fr
om
95
%
to
10
0%
ac
ro
ss
ge
no
ty
pe
s;
es
tim
at
es
w
er
e
co
ns
is
te
nt
in
su
bg
ro
up
an
al
ys
es
ba
se
d
on
st
ud
y
qu
al
ity
,g
eo
gr
ap
hi
c
se
tt
in
g,
fib
ro
si
ss
ta
tu
s,
pr
io
rt
re
at
m
en
te
xp
er
ie
nc
e,
an
d
ot
he
rf
ac
to
rs
;
re
su
lts
w
er
e
al
so
si
m
ila
ri
n
tr
ia
ls
th
at
st
ra
tif
ie
d
pa
tie
nt
sa
cc
or
di
ng
to
ag
e,
se
x,
ra
ce
or
et
hn
ic
ity
,o
rt
re
at
m
en
te
xp
er
ie
nc
e
Co
ns
is
te
nt
;
pr
ec
is
e
Go
od
Al
ls
tu
di
es
w
er
e
in
du
st
ry
-f
un
de
d
M
os
tD
AA
st
ud
ie
sd
id
no
ti
nc
lu
de
a
no
n-
DA
A
co
m
pa
ris
on
gr
ou
p
Ev
id
en
ce
w
as
m
os
tr
ob
us
tf
or
ge
no
ty
pe
1
an
d
m
or
e
lim
ite
d
fo
r
ge
no
ty
pe
s2
th
ro
ug
h
6
H
ig
h
SV
R
ra
te
sb
as
ed
on
cu
rr
en
tly
re
co
m
m
en
de
d
DA
A
re
gi
m
en
s
Tr
ia
ls
di
d
no
te
nr
ol
la
hi
gh
pr
op
or
tio
n
of
pa
tie
nt
sw
ith
ci
rr
ho
si
sa
tb
as
el
in
e
M
os
ts
tu
di
es
en
ro
lle
d
pr
ed
om
in
an
tly
w
hi
te
pa
rt
ic
ip
an
ts
Pe
rs
on
sw
ith
cu
rr
en
to
rr
ec
en
td
ru
g
us
e
ex
cl
ud
ed
fr
om
m
os
tt
ria
ls
M
os
tt
ria
ls
w
er
e
co
nd
uc
te
d
in
th
e
US
or
Eu
ro
pe
or
w
er
e
m
ul
tin
at
io
na
l
KQ
7:
Ef
fe
ct
of
tr
ea
tm
en
to
n
SV
R—
ad
ol
es
ce
nt
s
Pr
io
rr
ev
ie
w
:N
A
N
ew
ev
id
en
ce
:7
no
nr
an
do
m
iz
ed
tr
ea
tm
en
t
st
ud
ie
s(
n
=
34
8)
In
7
tr
ea
tm
en
ts
tu
di
es
,t
he
SV
R
ra
te
ra
ng
ed
fr
om
97
%
to
10
0%
Ra
te
sw
er
e
si
m
ila
rw
he
n
st
ra
tif
ie
d
ac
co
rd
in
g
to
DA
A
tr
ea
tm
en
t
re
gi
m
en
,g
en
ot
yp
e,
an
d
tr
ea
tm
en
th
is
to
ry
Co
ns
is
te
nt
;
im
pr
ec
is
e
Fa
ir
Ev
id
en
ce
in
ad
ol
es
ce
nt
sw
ith
ge
no
ty
pe
2
an
d
4
in
fe
ct
io
n
w
as
ve
ry
lim
ite
d
(n
=
20
)
Fo
ur
st
ud
ie
sw
er
e
in
du
st
ry
-f
un
de
d
Fa
ir
Th
re
e
st
ud
ie
se
va
lu
at
ed
DA
A
re
gi
m
en
s
no
tF
DA
-a
pp
ro
ve
d
fo
ru
se
in
ad
ol
es
ce
nt
s
Fo
ur
st
ud
ie
sw
er
e
m
ul
tin
at
io
na
l
(p
rim
ar
ily
US
an
d
Eu
ro
pe
)a
nd
3
w
er
e
co
nd
uc
te
d
in
Eg
yp
t
KQ
8:
H
ar
m
so
ft
re
at
m
en
t—
ad
ul
ts
:D
AA
vs
pl
ac
eb
o
4
Ra
nd
om
iz
ed
tr
ia
ls
(n
=
21
13
)
Po
ol
ed
ad
ve
rs
e
ev
en
tr
at
es
,D
AA
vs
pl
ac
eb
o:
An
y
ad
ve
rs
e
ev
en
t(
4
tr
ia
ls
):
RR
,1
.1
2
(9
5%
CI
,1
.0
2-
1.
24
);
I2
=
46
%
Se
rio
us
ad
ve
rs
e
ev
en
ts
(4
tr
ia
ls
):
RR
,1
.9
0
(9
5%
CI
,0
.7
3-
4.
95
),
I2
=
0%
W
ith
dr
aw
al
du
e
to
ad
ve
rs
e
ev
en
ts
(4
tr
ia
ls
):
RR
,0
.4
7
(9
5%
CI
,
0.
14
-1
.5
8)
;I
2
=
14
%
H
ea
da
ch
e
(4
tr
ia
ls
):
RR
,1
.1
2
(9
5%
CI
,0
.9
1-
1.
37
);
I2
=
0%
N
au
se
a
(3
tr
ia
ls
):
RR
,1
.4
2
(9
5%
CI
,1
.0
0-
2.
03
);
I2
=
10
%
Di
ar
rh
ea
(2
tr
ia
ls
):
RR
,1
.5
3
(9
5%
CI
,0
.8
8-
2.
68
);
I2
=
29
%
Fa
tig
ue
(3
tr
ia
ls
):
RR
,1
.0
5
(9
5%
CI
,0
.7
8-
1.
40
);
I2
=
32
%
An
em
ia
(1
tr
ia
l)
:R
R,
2.
21
(9
5%
CI
,0
.1
1-
46
)
Co
ns
is
te
nt
;
pr
ec
is
e
Fa
ir
Fe
w
tr
ia
ls
co
m
pa
re
d
a
DA
A
re
gi
m
en
w
ith
pl
ac
eb
o
Re
po
rt
in
g
of
m
et
ho
ds
us
ed
to
as
se
ss
an
d
de
fin
e
w
as
su
bo
pt
im
al
Tr
ia
ls
di
d
no
tr
ep
or
tl
on
g-
te
rm
fo
llo
w
-u
p
M
od
er
at
e
Se
e
KQ
7
KQ
8:
H
ar
m
so
ft
re
at
m
en
t—
ad
ul
ts
:D
AA
vs
ot
he
ra
nt
iv
ira
lt
re
at
m
en
t
2
RC
Ts
(n
=
45
9)
Po
ol
ed
ad
ve
rs
e
ev
en
tr
at
es
,D
AA
vs
ot
he
ra
nt
iv
ira
lt
re
at
m
en
t:
An
y
ad
ve
rs
e
ev
en
t(
2
tr
ia
ls
):
RR
,0
.6
5
(9
5%
CI
,0
.5
0-
0.
84
);
I2
=
87
%
Se
rio
us
ad
ve
rs
e
ev
en
ts
(2
tr
ia
ls
):
RR
,0
.0
8
(9
5%
CI
,0
.0
2-
0.
34
);
I2
=
0%
H
ea
da
ch
e
(2
tr
ia
ls
):
RR
,0
.7
8
(9
5%
CI
,0
.5
8-
1.
04
);
I2
=
0%
W
ith
dr
aw
al
du
e
to
ad
ve
rs
e
ev
en
ts
(2
tr
ia
ls
):
RR
,0
.0
6
(9
5%
CI
,
0.
01
-0
.2
9)
;I
2
=
0%
Fa
tig
ue
(2
tr
ia
ls
):
RR
,0
.3
7
(9
5%
CI
,0
.2
1-
0.
63
);
I2
=
32
%
H
ea
da
ch
e
(2
tr
ia
ls
):
RR
,0
.7
0
(9
5%
CI
,0
.5
2-
0.
95
);
I2
=
0%
N
au
se
a
(2
tr
ia
ls
):
RR
,0
.3
1
(9
5%
CI
,0
.1
6-
0.
59
);
I2
=
65
%
An
em
ia
(2
tr
ia
ls
):
RR
,0
.0
9
(9
5%
CI
,0
.0
4-
0.
23
);
I2
=
41
%
Ra
sh
(2
tr
ia
ls
):
RR
,0
.1
9
(9
5%
CI
,0
.0
6-
0.
58
);
I2
=
48
%
Co
ns
is
te
nt
;
pr
ec
is
e
Fa
ir
Fe
w
tr
ia
ls
co
m
pa
re
d
a
DA
A
re
gi
m
en
w
ith
an
ol
de
ra
nt
iv
ira
lr
eg
im
en
Re
po
rt
in
g
of
m
et
ho
ds
us
ed
to
as
se
ss
an
d
de
fin
e
w
as
su
bo
pt
im
al
Tr
ia
ls
di
d
no
tr
ep
or
tl
on
g-
te
rm
fo
llo
w
-u
p
M
od
er
at
e
Se
e
KQ
7
(c
on
tin
ue
d)
Clinical Review & Education US Preventive Services Task Force USPSTF Report: Screening for Hepatitis C Virus Infection in Adolescents and Adults
986 JAMA March 10, 2020 Volume 323, Number 10 (Reprinted) jama.com
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Portland State University User  on 04/13/2020
Ta
bl
e.
Su
m
m
ar
y
of
Ev
id
en
ce
(c
on
tin
ue
d)
St
ud
y
de
si
gn
Su
m
m
ar
y
of
fin
di
ng
s
Co
ns
is
te
nc
y
an
d
pr
ec
is
io
n
O
ve
ra
ll
qu
al
ity
Bo
dy
of
ev
id
en
ce
lim
ita
tio
ns
EP
C
as
se
ss
m
en
t
of
st
re
ng
th
of
ev
id
en
ce
fo
rK
Q
Ap
pl
ic
ab
ili
ty
KQ
8:
H
ar
m
so
ft
re
at
m
en
t—
ad
ul
ts
:o
ve
ra
ll
Pr
io
rr
ev
ie
w
:N
A
(o
ut
da
te
d
re
gi
m
en
s)
N
ew
ev
id
en
ce
:4
9
tr
ea
tm
en
t
st
ud
ie
s(
n
=
10
18
1)
Po
ol
ed
ad
ve
rs
e
ev
en
ts
ra
te
sf
or
cu
rr
en
tly
re
co
m
m
en
de
d
DA
A
re
gi
m
en
s:
An
y
ad
ve
rs
e
ev
en
t(
44
st
ud
ie
s)
:7
3.
3%
(9
5%
CI
,6
8.
0%
-7
8.
1%
);
I2
=
95
%
Se
rio
us
ad
ve
rs
e
ev
en
ts
(4
4
st
ud
ie
s)
:1
.9
%
(9
5%
CI
,1
.5
%
-2
.4
%
);
I2
=
33
%
W
ith
dr
aw
al
du
e
to
ad
ve
rs
e
ev
en
ts
(4
4
st
ud
ie
s)
:0
.4
%
(9
5%
CI
,
0.
3%
-0
.6
%
);
I2
=
0%
An
em
ia
(1
3
st
ud
ie
s)
:2
.4
%
(9
5%
CI
,0
.9
%
-6
.3
%
);
I2
=
85
%
Fa
tig
ue
(3
7
st
ud
ie
s)
:1
8.
4%
(9
5%
CI
,1
5.
6%
-2
1.
7%
);
I2
=
90
%
H
ea
da
ch
e
(4
2
st
ud
ie
s)
:1
8.
7%
(9
5%
CI
,1
5.
6%
-2
2.
2%
);
I2
=
90
%
In
so
m
ni
a
(1
8
st
ud
ie
s)
:8
.1
%
(9
5%
CI
,6
.7
%
-9
.9
%
);
I2
=
58
%
N
au
se
a
(3
6
st
ud
ie
s)
:1
1.
1%
(9
5%
CI
,9
.1
%
-1
3.
5%
);
I2
=
82
%
Di
ar
rh
ea
(1
9
st
ud
ie
s)
:8
.7
%
(9
5%
CI
,7
.0
%
-1
0.
8%
);
I2
=
69
%
Vo
m
iti
ng
(6
st
ud
ie
s)
:5
.8
%
(9
5%
CI
,3
.4
%
-9
.7
%
);
I2
=
43
%
Ra
sh
(1
7
st
ud
ie
s)
:5
.4
%
(9
5%
CI
,4
.1
%
to
7.
1%
);
I2
=
70
%
Co
ns
is
te
nt
;
pr
ec
is
e
Fa
ir
Es
tim
at
es
w
er
e
w
ith
ou
ta
no
n-
DA
A
co
m
pa
ris
on
gr
ou
p
Re
po
rt
in
g
of
m
et
ho
ds
us
ed
to
as
se
ss
an
d
de
fin
e
w
as
su
bo
pt
im
al
St
ud
ie
sd
id
no
tr
ep
or
tl
on
g-
te
rm
fo
llo
w
-u
p
M
od
er
at
e
Se
e
KQ
7
KQ
8:
H
ar
m
so
ft
re
at
m
en
t—
ad
ol
es
ce
nt
s
Pr
io
rr
ev
ie
w
:N
A
N
ew
ev
id
en
ce
:7
tr
ea
tm
en
t
st
ud
ie
s(
n
=
34
8)
Fi
ve
st
ud
ie
sr
ep
or
te
d
no
w
ith
dr
aw
al
sd
ue
to
ad
ve
rs
e
ev
en
ts
Th
er
e
w
as
1
se
rio
us
ad
ve
rs
e
ev
en
t(
gr
ad
e
3
jo
in
ti
nj
ur
y)
in
1
st
ud
y
Th
e
ra
te
of
an
y
ad
ve
rs
e
ev
en
tw
as
27
%
in
1
st
ud
y
an
d
71
%
-8
7%
in
4
st
ud
ie
s
Sp
ec
ifi
c
ad
ve
rs
e
ev
en
tr
at
es
:
H
ea
da
ch
e
(7
st
ud
ie
s)
:3
%
-4
8%
Fa
tig
ue
(7
st
ud
ie
s)
:5
%
-5
3%
Ga
st
ro
in
te
st
in
al
ad
ve
rs
e
ev
en
ts
(5
st
ud
ie
s)
:3
%
-2
8%
In
so
m
ni
a
(1
st
ud
y)
:2
3%
In
co
ns
is
te
nt
;
im
pr
ec
is
e
Fa
ir
St
ud
ie
sd
id
no
th
av
e
a
no
n-
DA
A
co
m
pa
ris
on
gr
ou
p
Th
er
e
w
as
hi
gh
va
ria
bi
lit
y
in
ad
ve
rs
e
ev
en
tr
at
es
,w
ith
no
cl
ea
rt
re
nd
s
w
he
n
re
su
lt
sw
er
e
st
ra
tif
ie
d
ac
co
rd
in
g
to
re
gi
m
en
Re
po
rt
in
g
of
m
et
ho
ds
us
ed
to
as
se
ss
ha
rm
sw
as
su
bo
pt
im
al
an
d
lo
ng
-t
er
m
fo
llo
w
-u
p
(>
48
w
k)
w
as
no
tr
ep
or
te
d
Fa
ir
Se
e
KQ
6—
ad
ol
es
ce
nt
s
KQ
9:
As
so
ci
at
io
n
be
tw
ee
n
SV
R
an
d
he
al
th
ou
tc
om
es
Pr
io
rr
ev
ie
w
:1
9
co
ho
rt
st
ud
ie
s
(n
=
30
69
2)
N
ew
ev
id
en
ce
:3
0
st
ud
ie
s
(n
=
11
6
65
9
[n
=
26
19
1
fr
om
co
ho
rt
st
ud
ie
si
nc
lu
de
d
in
th
e
pr
io
rr
ep
or
t
+
n
=
90
46
8
fr
om
ne
w
st
ud
ie
s]
)
Po
ol
ed
es
tim
at
es
fo
rh
ea
lth
ou
tc
om
es
fo
rS
VR
vs
no
SV
R,
in
st
ud
ie
s
in
w
hi
ch
<2
5%
of
th
e
po
pu
la
tio
n
ha
d
ci
rr
ho
si
sa
tb
as
el
in
e:
Al
l-
ca
us
e
m
or
ta
lit
y
(1
3
st
ud
ie
s,
5
ne
w
):
H
R,
0.
40
(9
5%
CI
,
0.
28
-0
.5
6)
;I
2
=
52
%
Li
ve
rm
or
ta
lit
y
(4
st
ud
ie
s,
0
ne
w
):
H
R,
0.
11
(9
5%
CI
,0
.0
4-
0.
27
);
I2
=
0%
Ci
rr
ho
si
s(
4
co
ho
rt
sr
ep
or
te
d
in
3
st
ud
ie
s,
al
ln
ew
):
H
R,
0.
36
(9
5%
CI
,0
.3
3-
0.
40
);
I2
=
0%
H
ep
at
oc
el
lu
la
rc
ar
ci
no
m
a
(2
0
st
ud
ie
s,
16
ne
w
):
H
R,
0.
29
(9
5%
CI
,
0.
23
-0
.3
8)
;I
2
=
19
%
Es
tim
at
es
w
er
e
co
ns
is
te
nt
in
an
al
ys
es
st
ra
tif
ie
d
ac
co
rd
in
g
to
du
ra
tio
n
of
fo
llo
w
-u
p,
ge
og
ra
ph
ic
se
tt
in
g,
an
d
le
ve
lo
fs
ta
tis
tic
al
ad
ju
st
m
en
tf
or
po
te
nt
ia
lc
on
fo
un
de
rs
Co
ns
is
te
nt
,
pr
ec
is
e
Fa
ir
St
ud
ie
sa
re
ob
se
rv
at
io
na
la
nd
su
sc
ep
tib
le
to
co
nf
ou
nd
in
g
So
m
e
st
ud
ie
sa
pp
ea
re
d
to
ev
al
ua
te
ov
er
la
pp
in
g
pa
tie
nt
po
pu
la
tio
ns
Ab
ou
th
al
f(
13
)o
ft
he
st
ud
ie
sd
id
no
t
ad
dr
es
s4
pr
es
pe
ci
fie
d
po
te
nt
ia
l
co
nf
ou
nd
er
si
n
an
al
ys
es
(a
ge
,s
ex
,
fib
ro
si
ss
ta
ge
,a
nd
ge
no
ty
pe
)
Fa
ir
M
os
ts
tu
di
es
ev
al
ua
te
d
SV
R
af
te
r
in
te
rf
er
on
-b
as
ed
th
er
ap
y;
ev
id
en
ce
on
SV
R
af
te
rD
AA
th
er
ap
y
w
as
lim
ite
d
to
2
st
ud
ie
s,
on
e
of
w
hi
ch
re
po
rt
ed
im
pr
ec
is
e
es
tim
at
es
.
St
ud
ie
sd
id
no
te
nr
ol
la
hi
gh
pr
op
or
tio
n
of
pa
tie
nt
sw
ith
ci
rr
ho
si
sa
tb
as
el
in
e
Pa
tie
nt
sp
rim
ar
ily
re
ce
iv
ed
in
te
rf
er
on
-c
on
ta
in
in
g
th
er
ap
y
Si
x
of
7
US
st
ud
ie
sc
on
du
ct
ed
in
VA
po
pu
la
tio
ns
M
or
e
th
an
on
e-
ha
lf
of
st
ud
ie
s
co
nd
uc
te
d
in
As
ia
,b
ut
re
su
lts
si
m
ila
r
in
US
/E
ur
op
e
st
ud
ie
s
Ab
br
ev
ia
tio
ns
:D
AA
,d
ire
ct
-a
ct
in
g
an
tiv
ira
l;
EP
C,
Ev
id
en
ce
-b
as
ed
Pr
ac
tic
e
Ce
nt
er
;F
DA
,U
S
Fo
od
an
d
D
ru
g
Ad
m
in
ist
ra
tio
n;
H
CV
,h
ep
at
iti
sC
vi
ru
s;
H
R,
ha
za
rd
ra
tio
;K
Q
,k
ey
qu
es
tio
n;
N
A,
no
ta
pp
lic
ab
le
;
N
N
S,
nu
m
be
rn
ee
de
d
to
sc
re
en
;R
CT
,r
an
do
m
iz
ed
cl
in
ic
al
tr
ia
l;
RR
,r
el
at
iv
e
ris
k;
SV
R,
su
st
ai
ne
d
vi
ro
lo
gi
cr
es
po
ns
e;
VA
,V
et
er
an
sA
ffa
irs
.
USPSTF Report: Screening for Hepatitis C Virus Infection in Adolescents and Adults US Preventive Services Task Force Clinical Review & Education
jama.com (Reprinted) JAMA March 10, 2020 Volume 323, Number 10 987
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Portland State University User  on 04/13/2020
randomized trials of treatment vs no treatment would be ethically
challenging and difficult to carry out. Alternatively, large cohort stud-
ies that measure important confounders could be highly informa-
tive. Trials and cohort studies that measure effects on quality of life,
function, and extrahepatic effects of HCV infection would also be
helpful for understanding effects of DAA regimens on these shorter-
term clinical outcomes. Studies on the association between SVR af-
ter DAA therapy and clinical outcomes would help to verify the link
between SVR and clinical outcomes with current DAA therapies. Ad-
ditional studies would be helpful for confirming the effectiveness
of DAA regimens in adolescents, including long-term outcomes.114
Well-designed prospective studies are needed to understand the ef-
fects of different HCV screening strategies, including repeat screen-
ing, on diagnostic yield.
Limitations
This review has several limitations. First, because there were few
randomized trials of current DAA regimens, nonrandomized treat-
ment studies were included, among which were studies without a
non-DAA therapy comparison group. Causality cannot be con-
cluded from such studies. Nonetheless, such studies were consid-
ered highly informative for SVR, an objective measure with rates
without treatment close to zero. However, more subjective out-
comes such as quality of life, function, and adverse events are
more difficult to interpret in the absence of randomization or a
comparison group. Second, no study of DAA therapy was con-
ducted in screen-detected patients, and few studies reported
presence or severity of baseline symptoms. Therefore, to evaluate
effectiveness of DAA therapies in populations likely to be identi-
fied by screening, this report selected studies based on proxy fac-
tors, specifically a low prevalence of cirrhosis and prior DAA expe-
rience. Research studies of DAA therapy could overestimate SVR
rates compared with typical clinical practice. However, observa-
tional studies reported SVR rates of 90%, only modestly lower
than observed in the trials.115,116
Third, some studies of DAA therapy in adolescents evaluated
regimens approved for adults but not children. Fourth, evidence on
potential long-term harms of DAA therapy exposure was limited.
However, limited evidence indicates no increased risk of hepato-
cellular carcinoma with DAA therapy compared with interferon-
based therapy through around 3 years of follow-up.68
Fifth, non–English-language articles were excluded. Sixth, for-
mal assessment for small sample effects (a potential marker of pub-
lication bias) using graphical or statistical methods was not per-
formed because of the small number of randomized trials.
Conclusions
Direct evidence on the effects of HCV screening on clinical out-
comes remains unavailable, but all-oral DAA regimens were associ-
ated with SVR rates greater than 95% and few short-term harms rela-
tive to older antiviral therapies. An SVR after antiviral therapy was
associated with improved clinical outcomes compared with no SVR.
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